Total Payments
$528,751
2024 Payments
$78,243
Companies
39
Transactions
1,102
Medicare Patients
10,677
Medicare Billing
$819,654
Payment Breakdown by Category
Research$478,215 (90.4%)
Consulting$35,278 (6.7%)
Food & Beverage$14,068 (2.7%)
Travel$909.52 (0.2%)
Education$280.94 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $478,215 | 441 | 90.4% |
| Consulting Fee | $35,278 | 21 | 6.7% |
| Food and Beverage | $14,068 | 632 | 2.7% |
| Travel and Lodging | $909.52 | 2 | 0.2% |
| Education | $280.94 | 6 | 0.1% |
Payments by Type
Research
$478,215
441 transactions
General
$50,536
661 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $513,493 | 462 | $0 (2024) |
| Amgen Inc. | $1,778 | 112 | $0 (2024) |
| AngioDynamics, Inc. | $1,401 | 4 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $1,373 | 69 | $0 (2024) |
| PFIZER INC. | $948.08 | 48 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $946.32 | 68 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $858.16 | 48 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $812.90 | 30 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $674.43 | 30 | $0 (2024) |
| Abbott Laboratories | $648.36 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78,243 | 103 | ABBVIE INC. ($76,495) |
| 2023 | $70,742 | 119 | AbbVie Inc. ($69,120) |
| 2022 | $100,876 | 151 | ABBVIE INC. ($99,315) |
| 2021 | $88,944 | 171 | AbbVie Inc. ($87,728) |
| 2020 | $25,392 | 97 | AbbVie Inc. ($22,819) |
| 2019 | $48,926 | 148 | AbbVie, Inc. ($46,648) |
| 2018 | $46,455 | 138 | AbbVie, Inc. ($44,752) |
| 2017 | $69,172 | 175 | AbbVie, Inc. ($66,616) |
All Payment Transactions
1,102 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA (Device) | Food and Beverage | In-kind items and services | $128.90 | General |
| Category: Transcatheter Heart Valves | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.99 | General |
| Category: Cardiovascular | ||||||
| 11/21/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.40 | General |
| 11/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.87 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.95 | General |
| 09/21/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.55 | General |
| 09/18/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $124.28 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 09/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/12/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $7,824.00 | Research |
| Study: This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects | ||||||
| 09/12/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants | ||||||
| 09/09/2024 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $162.08 | General |
| Category: Vascular | ||||||
| 08/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Cardiology | ||||||
| 08/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/12/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.64 | General |
| Category: Cardiovascular | ||||||
| 08/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/01/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $30,456.00 | Research |
| Study: This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects | ABBVIE INC. | $51,696 | 5 |
| A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults | AbbVie Inc. | $33,666 | 12 |
| A First in Human, Single and Multiple Ascending Dose and Food Effect Study for the Safety and Assessment of Pharmacokinetics of ABBV-576 | ABBVIE INC. | $25,619 | 8 |
| A Phase 1 Exploratory Study to Evaluate the Effect of ABBV-157 on QTc Interval | ABBVIE INC. | $23,304 | 8 |
| A Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of ABBV-668 in Healthy Adult Subjects | ABBVIE INC. | $20,458 | 9 |
| A First-in-Human Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses of ABBV-668 in Western and Asian Subjects and to Evaluate the Effects of Food and Itraconazole on the Safety and Pharmacokinetics of ABBV-668 in Western Subjects | ABBVIE INC. | $17,018 | 14 |
| A Multiple Ascending Dose and Food Effect Study for the Assessment of Pharmacokinetics and Safety of ABBV-111 | ABBVIE INC. | $15,728 | 12 |
| Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navocaftor and ABBV-119 and Potential of Navocaftor and ABBV-119 on CYP3A Induction in Healthy Volunteers | ABBVIE INC. | $15,720 | 12 |
| A Phase 1 Single Dose, Multiple Dose, Food Effect, and Drug-Drug Interaction First-in-Human Study of ABBV-CLS-7262 | ABBVIE INC. | $15,264 | 10 |
| A First in Human, Single and Multiple Ascending Dose and Food Effect Study of ABBV-191 | ABBVIE INC. | $14,420 | 13 |
| M19-529 | AbbVie, Inc. | $14,040 | 5 |
| A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants | AbbVie Inc. | $12,780 | 3 |
| Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants | AbbVie Inc. | $11,904 | 14 |
| M20-015 | AbbVie Inc. | $9,128 | 9 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Patients With Generalized Anxiety Disorder (GAD) and Patients With Schizophrenia (SCZ) | ABBVIE INC. | $7,014 | 7 |
| A Randomized, Double-blind, Placebo-controlled, Phase 1a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-382 in Healthy Adult Volunteers | ABBVIE INC. | $6,984 | 15 |
| A First in Human, Single and Multiple Ascending Dose and Food Effect Study for the Assessment of Pharmacokinetics and Safety of ABBV-119 | ABBVIE INC. | $6,176 | 11 |
| M19-775 | AbbVie Inc. | $5,360 | 4 |
| A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants | ABBVIE INC. | $5,116 | 7 |
| A Food-Effect Study for the Safety and Assessment of Pharmacokinetics of Navocaftor and Galicaftor. | ABBVIE INC. | $4,896 | 1 |
| Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants | ABBVIE INC. | $4,852 | 4 |
| Cystic Fibrosis: A First in Human, Single Ascending Dose Study of ABBV-111 | ABBVIE INC. | $4,312 | 5 |
| A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults | ABBVIE INC. | $4,012 | 3 |
| M19-172 | AbbVie, Inc. | $3,592 | 8 |
| Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants | ABBVIE INC. | $3,443 | 9 |
| M19-968 | AbbVie Inc. | $3,088 | 4 |
| A Study to Evaluate the Pharmacokinetics Safety and Tolerability of ABBV-932 in Healthy Adult Subjects Patients With Generalized Anxiety Disorder (GAD) and Patients With Schizophrenia (SCZ) | ABBVIE INC. | $2,874 | 4 |
| A First-in-Human Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses of ABBV-668 in Western and Asian Subjects and to Evaluate the Effects of Food and Itraconazole on the Safety and Pharmacokinetics of ABBV-668 in Western Subjects | AbbVie Inc. | $2,872 | 1 |
| A First in Human, Single and Multiple Ascending Dose and Food Effect Study for the Safety and Assessment of Pharmacokinetics of ABBV-576 | AbbVie Inc. | $2,688 | 1 |
| Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navocaftor and ABBV-111 and Potential of ABBV-111 for CYP3A Induction in Healthy Volunteers | ABBVIE INC. | $2,248 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-916 in Healthy Adult Subjects | ABBVIE INC. | $2,220 | 11 |
| A first in human single and multiple ascending dose and food effect study of ABBV-191 | AbbVie Inc. | $1,944 | 1 |
| A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262 | ABBVIE INC. | $1,900 | 1 |
| M20-051 | AbbVie Inc. | $1,512 | 1 |
| A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses of ABBV-022 in Healthy Adults | ABBVIE INC. | $1,392 | 10 |
| A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-916 in Healthy Adult Subjects | AbbVie Inc. | $936.00 | 1 |
| assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants and patients with Generalized Anxiety Disorder (GAD) and patients with schizophrenia (SCZ | AbbVie Inc. | $902.00 | 3 |
| A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) | AbbVie Inc. | $640.00 | 3 |
| M20-103 | AbbVie Inc. | $344.00 | 2 |
| A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Effect of a High Fat Meal on the Pharmacokinetics of Armour Thyroid Tablets in a Two-Regimen, Two-Sequence, Two Period Crossover Design and Assess Dose Proportionality in a Three-Regimen, Parallel Design in Healthy Subjects | ABBVIE INC. | $336.00 | 6 |
| Phase 1 Study to Assess the Pharmacokinetics, Safety and Tolerability of the Co-Administration of Rosuvastatin or Atorvastatin with ABBV-157 in Healthy Adult Subjects | ABBVIE INC. | $312.00 | 4 |
| M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) | AbbVie Inc. | $300.00 | 2 |
| A Multiple Ascending Dose and Food Effect Study for the Assessment of Pharmacokinetics and Safety of ABBV-111 | AbbVie Inc. | $288.00 | 1 |
| M20-070 | AbbVie, Inc. | $256.00 | 3 |
| M19-034 | AbbVie Inc. | $211.00 | 5 |
| Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants | ABBVIE INC. | $190.00 | 3 |
| M18-809 | AbbVie, Inc. | $184.00 | 1 |
| M19-117 | AbbVie Inc. | $176.00 | 2 |
| Venetoclax: Bioavailability Study of High Drug Lead Formulations | ABBVIE INC. | $162.00 | 3 |
| A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of AGN-190584 Preservative Free (PF) when Administered Bilaterally Once Daily in Subjects with Presbyopia | ABBVIE INC. | $150.00 | 1 |
| M17-220 | AbbVie, Inc. | $136.00 | 2 |
| A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects | ABBVIE INC. | $104.00 | 3 |
| Assessment of the Relative Bioavailability of ABBV-CLS-7262 Formulations in Healthy Adult Volunteers | ABBVIE INC. | $104.00 | 2 |
| A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects | AbbVie Inc. | $100.00 | 1 |
| A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants | ABBVIE INC. | $90.00 | 1 |
| This study is a randomized, three period, six sequence, single dose crossover design with ABBV-CLS-7262 in healthy adult subjects | ABBVIE INC. | $90.00 | 1 |
| A Phase 1 Bioavailability Study of Two Cedirogant (ABBV-157) Tablet Prototypes Relative to the Cedirogant Capsules and Determination of the Effect of Food on Cedirogant Tablet Prototypes | ABBVIE INC. | $72.00 | 2 |
| A Phase 1, Single-Arm, Open-Label Study to Assess the Safety and Tolerability of Glecaprevir/Pibrentasvir in Combination with an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Premenopausal Female Subjects | ABBVIE INC. | $72.00 | 5 |
| M19-116 | AbbVie Inc. | $64.00 | 1 |
| Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function | ABBVIE INC. | $60.00 | 2 |
| A Phase 1 Study to Evaluate the Bioavailability of Upadacitinib 45 mg Market-Image Formulation Compared to the Phase 3 Formulation and to Determine the Effect of Food on Upadacitinib 45 mg Market-Image Formulation | ABBVIE INC. | $48.00 | 2 |
| Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ABBV-0805 in Healthy Subjects | ABBVIE INC. | $48.00 | 1 |
| A Phase 1 Open-Label Drug-Drug Interaction Study Between ABBV-903 and Midazolam | AbbVie Inc. | $40.00 | 1 |
| A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults | ABBVIE INC. | $40.00 | 1 |
| A Comparative Pharmacokinetic Study of the Bioavailability of ABBV-951 and Levodopa-Carbidopa Intestinal Gel Plus Oral Carbidopa-Levodopa in Healthy Volunteers | ABBVIE INC. | $32.00 | 1 |
| M17-238 | AbbVie, Inc. | $32.00 | 3 |
| M19-306 | AbbVie, Inc. | $32.00 | 1 |
| M19-893 | AbbVie, Inc. | $32.00 | 1 |
| Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants | AbbVie Inc. | $30.00 | 1 |
| M16-641 | AbbVie, Inc. | $24.00 | 1 |
| M19-952 | AbbVie, Inc. | $24.00 | 1 |
| A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers | ABBVIE INC. | $20.00 | 1 |
| to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants | AbbVie Inc. | $20.00 | 1 |
| M18-764 | AbbVie, Inc. | $16.00 | 1 |
| M19-034 | AbbVie, Inc. | $16.00 | 1 |
| Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. | AbbVie Inc. | $10.00 | 1 |
| M16-856 | AbbVie, Inc. | $8.00 | 1 |
| M19-648 | AbbVie, Inc. | $8.00 | 1 |
| M20-017 | AbbVie, Inc. | $8.00 | 1 |
| M20-132 | AbbVie Inc. | $8.00 | 1 |
| M20-200 | AbbVie Inc. | $8.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,358 | 3,554 | $707,935 | $177,001 |
| 2022 | 28 | 2,434 | 3,614 | $719,696 | $180,544 |
| 2021 | 28 | 2,736 | 4,111 | $849,011 | $223,189 |
| 2020 | 32 | 3,149 | 4,712 | $944,489 | $238,920 |
Total Patients
10,677
Total Services
15,991
Medicare Billing
$819,654
Procedure Codes
120
All Medicare Procedures & Services
120 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 345 | $68,655 | $33,864 | 49.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 147 | 232 | $59,856 | $30,690 | 51.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 157 | 317 | $166,950 | $24,928 | 14.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 60 | 119 | $87,900 | $21,562 | 24.5% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 59 | 120 | $90,000 | $11,560 | 12.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 58 | 236 | $29,500 | $10,319 | 35.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 815 | 1,050 | $46,182 | $6,914 | 15.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $12,616 | $6,274 | 49.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 91 | $15,903 | $5,844 | 36.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 33 | $10,395 | $4,816 | 46.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 189 | 290 | $19,430 | $3,373 | 17.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 18 | 36 | $8,856 | $2,960 | 33.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 47 | 47 | $22,525 | $2,440 | 10.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 60 | 61 | $9,150 | $1,943 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $4,544 | $1,572 | 34.6% |
| 93017 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) | Office | 2023 | 62 | 63 | $16,002 | $1,478 | 9.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 20 | 56 | $3,248 | $1,249 | 38.4% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 64 | 65 | $3,900 | $1,029 | 26.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 19 | 54 | $3,672 | $928.80 | 25.3% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 18 | 20 | $2,200 | $915.23 | 41.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 58 | 59 | $8,850 | $778.21 | 8.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 64 | 65 | $9,100 | $690.00 | 7.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 43 | 48 | $480.00 | $403.20 | 84.0% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 14 | 15 | $5,835 | $280.56 | 4.8% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 16 | 17 | $1,088 | $161.16 | 14.8% |
About Dr. Isaac Thomas, MD
Dr. Isaac Thomas, MD is a Specialist healthcare provider based in Gurnee, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083662894.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Isaac Thomas, MD has received a total of $528,751 in payments from pharmaceutical and medical device companies, with $78,243 received in 2024. These payments were reported across 1,102 transactions from 39 companies. The most common payment nature is "" ($478,215).
As a Medicare-enrolled provider, Thomas has provided services to 10,677 Medicare beneficiaries, totaling 15,991 services with total Medicare billing of $819,654. Data is available for 4 years (2020–2023), covering 120 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Gurnee, IL
- Active Since 05/04/2006
- Last Updated 08/08/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1083662894
Products in Payments
- ELIQUIS (Drug) $1,280
- XARELTO (Drug) $1,251
- VENCLEXTA (Drug) $1,106
- Repatha (Biological) $1,071
- Adempas (Drug) $716.17
- Corlanor (Drug) $707.33
- ENTRESTO (Drug) $666.65
- JARDIANCE (Drug) $594.48
- PRALUENT (Drug) $520.96
- WATCHMAN (Device) $517.63
- VERQUVO (Drug) $428.27
- ONPATTRO (Drug) $368.59
- Definity (Drug) $367.05
- ARMOUR THYROID (Drug) $336.00
- LifeVest (Device) $290.09
- LEQVIO (Drug) $279.67
- Venclexta (Drug) $256.00
- CHANTIX (Drug) $240.99
- Mitra Clip system (Device) $229.72
- OPSUMIT (Drug) $217.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Gurnee
Dr. Benjamin Dubin, M.d, M.D
Specialist — Payments: $21,659
Specialist $21,659
Dr. Raymond Chow, M.d, M.D
Specialist — Payments: $18,162
Specialist $18,162
Ahmed Hashim, Md, MD
Specialist — Payments: $7,818
Specialist $7,818
Parthiv Shah, M.d, M.D
Specialist — Payments: $6,179
Specialist $6,179
Jaya Thomas, Md, MD
Specialist — Payments: $5,725
Specialist $5,725
Dr. Tien Cheng, M.d, M.D
Specialist — Payments: $5,132
Specialist $5,132